Overview

A Study of Ramucirumab (LY3009806) in Participants With Advanced Liver Cancer

Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to determine if the advised dose of ramucirumab is safe to be taken with chemotherapy treatment in participants with advanced liver tumors.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Fluorouracil
Leucovorin
Oxaliplatin
Ramucirumab